Home › Funds › REGENERON PHARMACEUTICALS, INC. › PBLS
REGENERON PHARMACEUTICALS, INC. position in PBLS
Parabilis Medicines, Inc. · Health Care
REGENERON PHARMACEUTICALS, INC. reported holding 4,166,666 shares of PBLS (Parabilis Medicines, Inc.) in its Q3 2026 13F filing — a position valued at US$134.5M, representing 74.90% of its reported portfolio and ranking #1 among its reported holdings. REGENERON PHARMACEUTICALS, INC. has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How REGENERON PHARMACEUTICALS, INC.'s PBLS position evolved
REGENERON PHARMACEUTICALS, INC. first disclosed a stake in PBLS in Q2 2026 at 4,166,666 shares (US$114.0M). The position peaked in Q3 2026 at 4,166,666 shares, worth US$134.5M. Across 2 filings, REGENERON PHARMACEUTICALS, INC. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 4,166,666 shares valued at US$134.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 4.17M | $114.04M | New |
| Q3 2026 | 4.17M | $134.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PBLS and 13F data
PBLS (Parabilis Medicines, Inc.) is a Health Care company. 90 other funds we track also report a position in PBLS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$791.9M), ARCH Venture Management, LLC (US$175.5M), venBio Partners LLC (US$144.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PBLS
- RA CAPITAL MANAGEMENT, L.P. 28.93M sh · $791.91M · Q2 2026
- ARCH Venture Management, LLC 6.41M sh · $175.52M · Q2 2026
- venBio Partners LLC 5.27M sh · $144.15M · Q2 2026
- Alphabet Inc. 4.92M sh · $134.65M · Q2 2026
- Nextech Invest Ltd. 4.66M sh · $127.63M · Q2 2026
- Cormorant Asset Management, LP 4.62M sh · $126.33M · Q2 2026
- Siren, L.L.C. 2.99M sh · $81.90M · Q2 2026
- Farallon Capital Management 2.37M sh · $64.82M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.37M sh · $64.82M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.92M sh · $52.57M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.88M sh · $51.47M · Q2 2026
- General Catalyst Group Management, LLC 1.60M sh · $43.82M · Q2 2026
More on REGENERON PHARMACEUTICALS, INC.
FAQ
How long has REGENERON PHARMACEUTICALS, INC. held PBLS?
REGENERON PHARMACEUTICALS, INC. has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is REGENERON PHARMACEUTICALS, INC.'s current position in PBLS?
As of Q3 2026, REGENERON PHARMACEUTICALS, INC. holds 4.17M shares of PBLS (Parabilis Medicines, Inc.), valued at $134.54M, representing 74.90% of its reported portfolio and ranking #1.
Has REGENERON PHARMACEUTICALS, INC. been buying or selling PBLS?
In the latest 13F filing (Q3 2026), REGENERON PHARMACEUTICALS, INC. held unchanged its position in PBLS. The position peaked in Q3 2026 at 4.17M shares.
Which other funds hold PBLS?
Other major institutional holders of PBLS include RA CAPITAL MANAGEMENT, L.P., ARCH Venture Management, LLC, venBio Partners LLC, among 90 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.